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 ^dZd 
Background:  Psychological morbidity in young people aged 10-24 years, with 
inflammatory bowel disease (IBD) is increased, but risk factors for and impact of this are 
unclear.  
Aim: To undertake a systematic literature review of the risk factors for and impact of 
psychological morbidity in young people with IBD.  
Methods: Electronic searches for English-language articles were performed with 
keywords relating to psychological morbidity according to DSM-IV and subsequent 
criteria; young people; and IBD in the MEDLINE, PsychInfo, Web of Science and CINAHL 
databases for studies published from 1994-September 2014.  
Results: 1444 studies were identified, of which 30 met the inclusion criteria.  The 
majority measured depression and anxiety symptoms, with a small proportion 
examining externalising behaviours.  Identifiable risk factors for psychological morbidity 
included: increased disease severity (r2=0.152, P <0.001), lower socioeconomic status 
(r2=0.046, P<0.001), corticosteroids (P <0.001), parental stress (r=0.35, P<0.001) and 
older age at diagnosis (r=0.28, P=0.0006).  Impacts of psychological morbidity in young 
people with IBD were wide-ranging and included abdominal pain (r=0.33; P< 0.001), 
sleep dysfunction (P< 0.05), psychotropic drug use (HR 4.16, 95% CI 2.76-6.27), non-
adherence to medication (12.6% reduction), and negative illness perceptions (r= -0.43). 
Conclusions:  Psychological morbidity affects young people with IBD in a range of ways, 
highlighting the need for psychological interventions to improve outcomes.  Identified 
risk factors provide an opportunity to develop targeted therapies for a vulnerable group. 
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Further research is required to examine groups under-represented in this review, such 
as those with severe IBD and those from ethnic minorities. 
 
INTRODUCTION 
Inflammatory Bowel Disease ?ŝŶĐůƵĚŝŶŐďŽƚŚƌŽŚŶ ?ƐŝƐĞĂƐĞĂŶĚhůĐĞƌĂƚŝǀĞŽůŝƚŝƐ 
affects an estimated 1.5million people in North America, 2.2 million people in Europe 
and several hundred thousand more worldwide with a globally rising incidence in 
children and young people (1 W3).  Around 20-30% of inflammatory bowel disease 
presents in childhood (4) with a peak onset in adolescence (1) and with a younger age at 
presentation being a risk factor for poor disease prognosis (5).  Young people living with 
inflammatory bowel disease face a range of issues and challenges that can represent a 
major psychosocial burden leading to a loss of self-esteem and self-confidence, poorer 
quality of life, and heightened levels of psychological distress (6).  Adolescents with 
inflammatory bowel disease have been estimated to be at 4.6 fold increased risk of 
clinically significant symptoms of anxiety or depression than healthy peers (7).  
Inflammatory bowel disease has also been demonstrated to have a detrimental impact 
ŽŶǇŽƵŶŐƉĞŽƉůĞ ?ƐĞĚƵĐĂƚŝŽŶ ?ĞŵƉůŽǇŵĞŶƚĂŶĚƌĞůĂƚŝŽnships (8,9).  Cognitive 
behavioural therapy has been demonstrated to improve mood and quality of life in 
adolescents with IBD and subsyndromal depression (10).  European guidelines 
recommend that patients with inflammatory bowel disease are screened for anxiety, 
depression and if indicated refer for psychotherapeutic interventions (11,12).  A recent 
worldwide survey of health care professionals caring for inflammatory bowel disease  
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patients perceive that mental health assessment should be standard IBD care (13).  
However, a defined pathway for referral is available in only 12% of UK adult 
inflammatory bowel disease centres, to which young people transition from the age of 
16, compared to two-thirds in paediatric care (14), and as a result psychological 
morbidity is frequently untreated in inflammatory bowel disease (15).   
 
Two reviews have examined aspects of psychological functioning and adjustment in 
young people with inflammatory bowel disease.  Greenley et al. (16) examined 
psychosocial adjustment of young people (<18 years) with inflammatory bowel disease.  
The review, which included only studies with a comparison group or those where 
published normative data was available, found that subjects with inflammatory bowel 
disease had higher rates of depressive disorders and internalising conditions compared 
to other chronic conditions such as cystic fibrosis, diabetes and malignancy.  Ross et al. 
(17) found an increased incidence of psychiatric disorders (anxiety and depression) using 
standard diagnostic interviews in young people (<18 years) with IBD.  However, 
identifying psychological morbidity in young people with inflammatory bowel disease is 
difficult due to the overlapping nature of symptoms which may be related to organic 
disease, adverse effects of medications or due to psychological morbidity (18).   
 
Furthermore, difficulties arise because studies and reviews classify young people 
according to differing age groups, with studies examining paediatric populations (<16 
years),  ‘youth ? (<18 years) or  ‘adults ? (>18 years).   The World Health Organisation 
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defines adolescence as the developmental stage between 10-19 years, and youth as 15-
24years.  In addition, classification, prevalence and incidence of psychological distress 
are difficult to define (16,19) due to lack of consistent use of diagnostic criteria of DSM-
IV (20) in research settings.  In line with World Health Organisation recommendations, 
this review treats two age groups (adolescence and youth) as a single group aged 10-
24years, referred to as young people throughout.  This age group is a critical time for 
young people, ǁŚĞŶƚŚĞǇĂƌĞůĞĂƌŶŝŶŐĂďŽƵƚƚŚĞŝƌĚŝƐĞĂƐĞ ?ƚƌĂŶƐŝƚŝŽŶŝŶŐĨƌŽŵĐŚŝůĚƌĞŶ ?Ɛ
service provision through to adult care, and from parent-led care to self-management 
whilst at a life stage characterised by change, exploration, risk-taking and identity 
development. 
 
Health care professionals managing young people with IBD need to be aware of the 
possible consequences of psychological morbidity and be adept at identifying those at 
risk of psychological morbidity.   This systematic review therefore aims to synthesize the 
available evidence regarding the impact of psychological morbidity in young people with 
inflammatory bowel disease and associated risk factors and to make recommendations 
regarding future research and service development in this area. 
 
Zs/tZ/dZ/EDd,KK>K'z 
This systematic review was conducted according to the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 
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Data Sources and Search Strategy 
A systematic literature search was undertaken using four relevant databases, Medline 
(via Ovid), PsycInfo (via Ovid), Web of Science, and CINAHL aiming to capture all relevant  
studies across disciplines including psychology, psychiatry, paediatric and adult 
gastroenterology from 1994 (to correspond to the introduction of the DSM-IV criteria) 
to 24th of September 2014.  ^ĞĂƌĐŚƚĞƌŵƐƌĞůĂƚŝŶŐƚŽƉƐǇĐŚŽůŽŐŝĐĂůŵŽƌďŝĚŝƚǇ ? “ŵĞŶƚĂů
ĚŝƐŽƌĚĞƌ ? ? “ƉƐǇĐŚŽůŽŐŝĐĂůŚĞĂůƚŚ ? ? “ŵĞŶƚĂůŚĞĂůƚŚ ? ? “ƉƐǇĐŚŽůŽŐŝĐĂůĚŝƐƚƌĞƐƐ ? ? “ŵŽŽĚ
ĚŝƐŽƌĚĞƌ ? ? “ĂĨĨĞĐƚŝǀĞĚŝƐŽƌĚĞƌ ? ? “ƐĐŚŝǌŽƉŚƌĞŶ ? ? ? “ƉƐǇĐŚŽƐŝƐ ? ? “ƉƐǇĐŚŽƚŝĐ ? ? “ƐŽŵĂƚŽĨŽƌŵ
ĚŝƐŽƌĚĞƌ ? ?  “ĞĂƚŝŶŐĚŝƐŽƌĚĞƌ ? ? “ĚĞƉƌĞƐƐ ? ? ? “ƉĞƌƐŽŶĂůŝƚǇĚŝƐŽƌĚĞƌ ? ? “ĂŶǆŝĞƚǇ ?), young 
ƉĞŽƉůĞ ? “ǇŽƵŶŐƉĞŽƉůĞ ? ? “ǇŽƵŶŐƉĞƌƐŽŶ ? ? “ǇŽƵŶŐĂĚƵůƚ ? ? “ǇŽƵƚŚ ? ? “ĂĚŽůĞƐĐĞŶƚ ? ? 
 “ĂĚŽůĞƐĐĞŶĐĞ ? ?  “ƚĞĞŶĂŐĞƌ ? ? “ƉĂĞĚŝĂƚƌŝĐ ? ? “ƉĞĚŝĂƚƌŝĐ ?, inflammatory bowel disease 
 ? “ŝŶĨůĂŵŵĂƚŽƌǇďŽǁĞůĚŝƐĞĂƐĞ ? ? “/ ? ? “ƌŽŚŶ ?Ɛ ?,  “hůĐĞƌĂƚŝǀĞŽůŝƚŝƐ ? ? “ĐŽůŝƚŝƐ ? ?ǁĞƌĞ
entered and combined, and limited to  ‘ĂĚŽůĞƐĐĞŶƚ ?ĂŶĚ ‘ǇŽƵŶŐĂĚƵůƚ ? ? 
 
Study eligibility and selection criteria 
Three authors (A.J.B, G.R, A.J.L) determined study eligibility.  Studies were initially 
screened by the first author; decisions about study inclusion were made independently 
by all three authors (A.J.B, G.R, A.J.L).  Studies were included if (a) published in full and 
written in English (b) utilised standardized measures of psychological morbidity or 
defined psychiatric disease by psychotropic drug use (c) used established valid and 
reliable questionnaires.  Studies were excluded if (a) psychological morbidity could not 
be extricated from the presented data (b) they were case studies or not empirical 
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studies (e.g. narrative reports, reviews), and (c) they were only published in abstract.  
Additional studies of interest were identified by hand searches of bibliographies and 
cited references and by consultation with clinical experts in the field. 
 
Data extraction and Quality Assessment 
30 studies were included for review (Figure 1; (21)).  Of these, 24 were conducted in 
North America and 6 in Europe.  The median number of participants in the studies was 
79 (range 20-2144), mean age 14.7 years (range 8-18years) with an inflammatory bowel 
disease type of 83% ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ; 16% ulcerative colitis and 1% inflammatory bowel 
disease unclassified.  A formal assessment of study quality was conducted using the 
GRADE system (22) with 15 (50%) being graded as low and 15 as very low in quality. 
28/30 studies reviewed were cohort, cross sectional designs investigating psychological 
morbidity, psychosocial burden and factors associated with these and related outcomes 
(see Tables 1, 2 and Supplementary on-line Information: Full Summary of Studies 
Included).  
 
Z^h>d^ 
RISK FACTORS FOR PSYCHOLOGICAL MORBIDITY 
Age at Diagnosis. Within this inflammatory bowel disease population, a later age of 
diagnosis may correlate with increased risk of psychological morbidity.  Szigethy et al. 
(23) found that a diagnosis at an older age correlated with a greater number of 
depressive symptoms (r=0.28, P=0.0006), independent of inflammatory bowel disease 
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duration.  Mackner et al. in 2006 (24) found that young people with inflammatory bowel 
disease diagnosed in adolescence had an increased report of somatic complaints 
(P<0.05) compared to those with childhood onset inflammatory bowel disease.  Despite 
these findings, the use of psychotropic drugs in young people with inflammatory bowel 
disease were not found to correlate with age at diagnosis (25), nor in various depression 
subtypes (26).   
 
Socioeconomic Status.  Three studies have found a significant relationship between 
socioeconomic status and depression in young people with IBD (27 W29), with two 
studies finding no association (30,31).  Clark et al. (27) found in multivariate model 
analysis that socioeconomic status was one of the strongest predictors of depressive 
symptoms in young people with ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ(r2=0.046, P <0.001).  Two further 
studies used family income as a socioeconomic status measure and found that a family 
income less than $75000 had higher total ŚŝůĚƌĞŶ ?ƐĞƉƌĞƐƐŝŽŶ/ŶǀĞŶƚŽƌǇ (32) scores 
than those with >$75000 (P= 0.023) (29), and higher depression scores came from lower 
income families (r= - 0.028) (28).  However, from the latter study conclusions are limited 
as details of family income cut offs are not presented, and a control group of 
participants with functional gastrointestinal symptoms are included within the analysis 
of those with inflammatory bowel disease. 
 
Gender.  Four studies have examined whether there is a relationship between gender 
and psychological morbidity in young people with inflammatory bowel disease, with 
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three studies suggesting no association (25,26,33).  However, in a larger study, Loftus 
and colleagues suggest gender may play a role in the young people of psychological 
morbidity young people with inflammatory bowel disease present with, and this is 
related to age of the young people with inflammatory bowel disease.  Teenage girls (age 
not further specified) had a two-fold increased risk of anxiety disorders (HR=2.45; 95% 
CI=1.41-4.25), whereas boys aged <12 years had an increased risk of depression 
(HR=2.55. 95% CI 1.1.5-5.67) (34).   
 
Ethnicity. The role ethnicity may play is uncertain.  All studies in this review report a 
significant Caucasian predominance in their cohorts.  However two studies, with small 
sample sizes of 50 and 56 participants, did not find an association between ethnicity and 
psychological morbidity in young people with IBD (30,35). 
 
Inflammatory Bowel Disease Activity and Severity.  Several studies have 
examined the relationship between inflammatory bowel disease severity and 
depression with a positive association observed  in 6 studies (23,27,29,31,36) but no 
association in 3 (30,33,37).  In the study of Clark et al. (27) a positive association was 
found between measures of disease activity (WĂĞĚŝĂƚƌŝĐƌŽŚŶ ?ƐŝƐĞĂƐĞĐƚŝǀŝƚǇ/ŶĚĞǆ
(38) and erythrocyte sedimentation rate) and depressive symptoms after controlling for 
predictors, in stepwise regression models (r2=0.152, P <0.001).  Reed-Knight and 
colleagues found greater depressive symptoms in the 14% of the cohort with 
moderate/severe disease activity compared to those with mild or inactive disease 
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activity (36).  Furthermore, this study evaluated the relationship between inflammatory 
markers and depressive symptoms and found a relationship with erythrocyte 
sedimentation rate (r = 0.30, p < 0.05) but not C - reactive protein (r=0.11, p= 0.44).  In a 
small study, disease severity was a significant predictor of self-reported depressive 
symptoms (B= 0.122, SE B 0.044, P<0.01), but not parent reported (29), although nearly 
80% of participants in this study had inactive or mild disease.  ŚŝůĚƌĞŶ ?ƐĞƉƌĞƐƐŝŽŶ
Inventory scores did not differ in those with inactive disease compared to those with 
moderate or severely active disease, nor between those following  acute, chronic 
intermittent or chronic disease courses (23).  No control groups was used for 
comparison however.  A pooled measure of disease severity  for ulcerative colitis 
(measured by Clinical Score of Kozarek (39)) and ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ(measured by 
WĂĞĚŝĂƚƌŝĐƌŽŚŶ ?ƐŝƐĞĂƐĞĐƚŝǀŝƚǇ/ŶĚĞǆ (38)) showed significantly increased mean 
depressive symptoms in the moderate/severe group compared with the inactive group 
(F (2.88)=4.171, P=0.019), and in those receiving systemic steroids (P=0.019) (23).  In a 
study based on both self-report and parent-report, young people with severe 
inflammatory bowel disease symptoms (measured only by self-report visual analogue 
scales) had greater internalising and externalising (behavioural) problems compared to 
those with mild disease activity (P< 0.01) (31).  
 
Of the studies reporting no relationship with disease severity and psychological 
morbidity one of these report that patients with mild inflammatory bowel disease 
diagnosed for > 1 year have psychosocial functioning similar to that of controls, and 
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disease severity did not differ in those with or without depressive symptoms (40).  
However, this study had a small sample size, a ƌŽŚŶ ?ƐĚŝƐĞĂƐĞpredominant cohort and 
93.6% of patients with mild or inactive disease).  In a second small study examining 
predictors of depression in new onset inflammatory bowel disease (<3months) Burke et 
al. (37) found that the depressed group had significantly less severe disease than the 
non-depressed group (P=0.006).  Finally, Herzog and colleagues examined ŚŝůĚƌĞŶ ?Ɛ
Depression Inventory scores and found no relationship with inflammatory markers (C - 
reactive protein) or disease scores (33).   
 
Inflammatory Bowel Disease Duration. No significant correlation has been 
demonstrated between duration of disease and psychological morbidity in a number of 
studies (23,30,31,33,41).  However, all of these studies include participants with a well-
established IBD diagnosis, with a mean duration of disease of 1.2- 5.4 years.  Therefore 
determining the risk that a diagnosis of inflammatory bowel disease may have on 
psychological morbidity within the first year of diagnosis is uncertain from the studies 
available.  Furthermore, details regarding inflammatory bowel disease diagnosis 
confirmation is frequently not provided.  
 
Inflammatory Bowel Disease Type.  Difference between inflammatory bowel 
disease type and relationship to psychological morbidity is detailed in 6 studies, with no 
significant difference reported between ulcerative colitis and ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ in young 
people and depressive symptoms (23,30,31,33,42) nor with antidepressant use (25).  
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Difficulty exists in interpreting these findings as studies have not been designed or 
powered sufficiently to determine effect of inflammatory bowel disease type on 
depressive/anxiety symptoms, and with ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ predominant cohorts in 2 
studies (23,40).   
 
 
Corticosteroids.  Five studies have examined corticosteroid use and 
anxiety/depressive symptoms, with four suggesting that corticosteroid use contributes 
to psychological morbidity (23,27,34,43).  Mrakotsky et al. (2012) compared a group of 
young people receiving high-dose corticosteroids (>30mg/day or 1mg/kg/day for more 
than 5days) with controls with inflammatory bowel disease but in clinical remission and 
off systemic steroids for more than 6months.  Parental-report of internalizing symptoms 
in ƌŽŚŶ ?ƐĚŝƐĞĂƐĞwere greater in the steroid group (P<0.001) (43).   A further study 
examining risk factors for depression in young people with inflammatory bowel disease 
found, after controlling for disease activity, that depressive symptoms were positively 
associated with steroid dose (P<0.01) (27).   Szigethy et al. (23) also found that young 
people receiving steroids were more likely than those without steroids to have clinically 
significant depressive symptoms with a ŚŝůĚƌĞŶ ?ƐĞƉƌĞƐƐŝŽŶ/ŶǀĞŶƚŽƌǇscore of >12 
(P=0.019).  In addition when specific symptoms of depression (anhedonia, sleep 
disturbance, fatigue, decreased appetite) were removed from the ŚŝůĚƌĞŶ ?ƐĞƉƌĞƐƐŝŽŶ
Inventory score there was no change in the correlation, suggesting that this finding is 
not related to disease severity (23).  Loftus et al. (34) who also considered anxiety 
related disorders found that the use of corticosteroids significantly increased the risk of 
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developing anxiety disorders (incidence of 3.04 per 100 patient years vs. 1.32 in 
controls), but not depression in young people with ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ.  In contrast Reed-
Knight and colleagues did not find a relationship between current, but lower oral steroid 
use (defined as budesonide >3 mg /day and/or prednisone >5mg/day) and ŚŝůĚƌĞŶ ?Ɛ
Depression Inventory score (36).   
 
Immunosuppressive Drugs.  The use of immunosuppressive drugs in young people 
with inflammatory bowel disease and psychological morbidity has been examined in 
three studies with no relationship found between the use of anti-TNF drugs, thiopurines 
and psychological morbidity.  A recent study focused on investigating anti-TNF 
(infliximab) as a predictor of depression in young people with CD (27).  Stepwise 
regression analysis indicated that infliximab use was not significantly associated with 
depressive symptoms (27).  The study excluded those on concurrent antidepressant 
therapy, those with comorbid psychiatric disorders or being treated with other anti-TNF 
agents (40/550 excluded), which may limit the generalizability of the findings.  In a 
further study investigating depression subtypes in young people with IBD, treatment 
with anti-TNF did not differ between the 3 subtypes of depression described (26).  
Depression in young people with inflammatory bowel disease was sub-divided by latent 
class analyses into the following subtypes: 1) mild depression, 2) somatic depression  W 
with significant symptoms of depressed affect and motor hypoactivity, and 3) cognitive 
despair  W with highest scores of suicidal ideation and hopelessness.  Significant 
differences between subtypes 1 and 2 were found with biological markers and scores of 
15 
 
inflammatory bowel disease activity.  Subgroup 3 was associated with a longer duration 
of IBD diagnosis and presence of a stoma.  This study is limited by the small numbers 
(n=13) in subgroup 3 and heterogeneity in inflammatory bowel disease phenotypes.  
Virta & Kolho (25) in a Finnish case controlled study of antidepressant use in young 
people with inflammatory bowel disease, found no significant association between 
immunosuppressant medication e.g. azathioprine and antidepressant use. 
 
Parental Stress. Four cross-sectional studies (29,37,44,45) and one longitudinal study 
(46) have found a significant relationship between parental stress or family factors and 
psychological morbidity.  Burke et al. (37) found those whose mothers had depression 
were significantly more likely to have depressive symptoms compared to those without 
a history of maternal depression (P=0.03).  A larger more recent study found that self-
report of internalizing symptoms was associated with parenting stress (r=0.35, P<0.001) 
and more frequent medically-related situations (r=0.26, P<0.01) as measured by The 
Paediatric Inventory for Parents (32), but a similar finding was not observed in those 
with externalising symptoms (45).  Significant exclusion criteria were another chronic 
illness, high risk treatment-associated behavioural and psychiatric symptoms and high 
dose steroids.  Family affective involvement (degree of family interest and involvement 
with one another) significantly predicted parent-report of young people depressive 
symptoms, but not self-report (B= 4.13, P= 0.05) as did family problem solving  (B= 5.49, 
P< 0.05) (29).  The only longitudinal study in this field examined young people receiving 
an amino-salicylate or thiopurine and depressive symptoms, with measures repeated at 
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6 months (46).  Baseline parenting stress accounted for a significant amount of the 
variance in depressive symptoms at follow up (r-change=0.53, P<0.05) suggesting that 
parenting stress impacts on young people depressive symptoms in inflammatory bowel 
disease. 
 
 
 
THE IMPACT OF PSYCHOLOGICAL MORBIDITY 
Medication Adherence. Understanding factors relating to adherence to medication 
in young people with inflammatory bowel disease and its relationship to psychological 
morbidity may help to identify if and when young people with inflammatory bowel 
disease may benefit from therapeutic and psychological interventions.  Of four cross-
sectional studies - all without controls  W that have examined the relationship between 
adherence to medication and depressive/anxiety symptoms, three suggest a 
relationship (47 W49).  Gray et al. (49) measured adherence by Medication Adherence 
Measure (50), and found that depression/anxiety symptoms moderated the relationship 
between Medication Adherence Measure endorsed barriers to adherence (e.g. forgot, 
refusal) and adherence.  Specifically in young people with high levels of 
anxiety/depressive symptoms, adherence was reduced by 12.6% (B= 0.43, P<0.001) in 
contrast to those with lower levels of anxiety/depressive symptoms (adherence 
reduction of 2%) where increasing other Medication Adherence Measure endorsed 
barriers to adherence did not affect adherence (49).  Hommel et al. (47) examined 
medication adherence by Medication Adherence Measure, pill counts and thiopurine 
active metabolite concentrations and found that depressive symptoms showed a weak 
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negative association with adherence measured by thiopurine active metabolite 
concentrations (r=-0.40, P<0.05) and amino-salicylate Medication Adherence Measure 
adherence (r=-0.56, P<0.01).  However, pill count adherence scores for 6-
mercaptopurine and aminosalicylate medications did not correlate with parent or self-
report quality of life (47).  Reed-Knight et al. (48) measured adherence with Medication 
Adherence Measure by self-report and parent-report with externalizing clinical scales 
measuring attention and conduct problems.  Attention and conduct problems showed a 
negative association with parent and self-report adherence (B= -0.038, SE= 0.0017, 
P<0.05).  In contrast, Mackner & Wallace (30) found no association with adherence and 
psychological morbidity when using a standard interview schedule to measure 
adherence, but biases in this study include a selective outpatient cohort in remission 
(inactive or mild disease in 94%) and a low response rate.   
 
Physical Symptoms. Abdominal pain may be a feature of both active disease and 
underlying psychological morbidity.  Thus, Srinath et al. (51) found that in depressed 
young people, inflammatory bowel disease related factors such as weight loss (r= 0.33, 
P= 0.001), diarrhoea (r= 0.34, P = 0.001), erythrocyte sedimentation rate  (r=0.22; 
P=0.02) were associated with abdominal pain (as measured by the self-report 
Abdominal Pain Index (52)), but so too were depressive symptoms (r=0.33; P < 0.001).  
Depression, weight loss, and abdominal tenderness (measured by PaediatriĐƌŽŚŶ ?Ɛ
Disease Activity Index) were the strongest predictors of pain for young people with 
ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ.  In ulcerative colitis the role psychological morbidity plays in abdominal 
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pain may be clearer, with only depressive severity predicting pain (51).   This suggests 
that psychological morbidity plays an important role in illness perceptions of young 
people with inflammatory bowel disease, which is, in turn, important when interpreting 
self-reported components of well-established disease activity measures.  
 
Health Care Utilization. The relationship between health care contact and 
psychological morbidity in young people with inflammatory bowel disease has been 
investigated with conflicting results (35,53).  Reigada et al. (53) found anxiety (measured 
with Screen for Child Anxiety-Related emotional Disorders (54)), and depressive 
symptoms (measured with Center for Epidemiological Studies depression Scale (55)) did 
not correlate with an increase in health-care contacts when controlled for current 
disease activity.  In contrast inflammatory bowel disease specific anxiety (defined as 
worry about impact of symptoms of inflammatory bowel disease in the last two weeks, 
and an un-validated measure) was associated with greater utilization of medical services 
(including inpatient admissions) and decreased social functioning compared to those 
with lower levels of inflammatory bowel disease specific-anxiety.  Ondersma et al. (35) 
found that depressive symptoms correlated with subjective symptoms and disability and 
also with an increased frequency of health care contact.  Details regarding 
measurement and analysis in the latter study are not provided and limitations exist with 
the measurement of health care contacts by self-report.   
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Psychotropic Drugs.  A clear, measurable manifestation of psychological morbidity is 
the use of pharmacological treatments for psychological indications.  Two large studies 
based on national registries in Finland (25) and North America (34) have shown an 
increased use of antidepressants in young people with inflammatory bowel disease.  The 
most recent of these, based on 3 national Finnish registries (25), examined the use of 
antidepressants in young people with recent onset inflammatory bowel disease, with a 
median follow up time from diagnosis of 2.1 years.  The cumulative incidence of 
antidepressant initiations after diagnosis with IBD was 1.2% and 2.4% at 2 and 3 years 
respectively, compared to 0.9% and 1.0% in age, sex matched healthy controls, with an 
almost 3-times greater use of antidepressants in inflammatory bowel disease compared 
to controls up to 3 years from diagnosis (3.2% vs 1.2%, P=0.031).  Loftus et al. (34) 
performed a large population study based on medical claims, prescription drug claims, 
and enrolment data in which they compared the risks of developing psychological 
morbidity (anxiety and depression) with the incidences of psychotropic medication.  
After controlling for patient characteristics including comorbidity profiles, health plan 
types and geographical variation, young people with ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ were 2-times more 
likely to receive psychotropic drugs than ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ-free age, sex and health plan 
enrolment matched controls.  The likelihood of receiving a tricyclic antidepressant in the 
ƌŽŚŶ ?ƐĚŝƐĞĂƐĞgroup was 4 times greater than controls (HR=4.16, 95% CI=2.76-6.27) 
(34).  This increase in tricyclic antidepressant use may in part be explained by functional 
bowel symptoms following CD diagnosis, but this was not assessed by the investigators.  
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Of note patients with any mental health disorders or psychotropic medication use 
before the index date were excluded. 
 
Sleep. The relationship between sleep and psychological morbidity in depressed young 
people with ƌŽŚŶ ?ƐĚŝƐĞĂƐĞhas been examined in two recent cross-sectional studies 
(56,57).  Benhayon and colleagues (56) assessed subjective sleep quality, daytime 
dysfunction, and sleep latency measured by Likert ratings in the Pittsburgh Sleep Quality 
Index (58).  Although sleep disturbances were greater in depressed young people with 
ƌŽŚŶ ?ƐĚŝƐĞĂƐĞ(compared to healthy controls without depression) the findings reveal a 
complex relationship between inflammatory bowel disease activity, psychological 
morbidity and various aspects of sleep.  Multivariate modelling suggests that qualitative 
measures of sleep (including sleep disturbance, daytime dysfunction, subjective sleep 
quality, and sleep latency) was predicted by anxiety (r2=11.0, P=0.001), disease activity 
(r2=19.2, P < 0.0001) and abdominal pain (r2=17.0, P< 0.0001) but not to biomarkers of 
inflammation (C - reactive protein).  In contrast the quantitative measures of sleep 
disturbance (including sleep duration and habitual sleep efficiency) were predicted by 
disease activity only (r2=18.3, P< 0.0001) (56).   Pirinen et al. found that the 20% of an 
inflammatory bowel disease cohort classified as sleep-troubled, reported higher rates of 
anxiety/depression (P< 0.05) and somatic complaints (P< 0.01) than those without 
sleep-trouble (57).  Mrakotsky et al. (43) reported greater sleep dysfunction in 
inflammatory bowel disease patients receiving corticosteroids and that this correlated 
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with depressive symptoms.  However, the small sample sizes result in poor statistical 
power in both studies in this field. 
 
Illness Perception. Subjective illness perception and its relationship with psychological 
morbidity has been investigated in two studies (28,35).  In the first study (35), 
depressive symptoms were measured through negative affectivity and were compared 
to subjective illness severity (pain, behaviour, fatigue).  Negative affectivity correlated 
significantly with subjective symptoms, and it was estimated that 34% of variance in 
subjective illness severity was accounted for by negative affectivity, whilst being 
unrelated to disease activity as measured by erythrocyte sedimentation rate.  The more 
recent study  examined illness perception and depressive symptoms in inflammatory 
bowel disease and a control group of young people with functional gastrointestinal 
complaints (28).  In this study the only independent variable to predict depressive 
symptoms was whether young people  “ƐĂǁƚŚĞŝƌŝůůŶĞƐƐĂƐĂƉƌŽďůĞŵ ? ?ƌA?-0.43) on the 
subjective well-being score, suggesting the role illness perceptions may play in 
psychological morbidity.  However, interpretation of these results is limited by the small 
sample size, the use of non-validated measures of illness perception and subsequent 
analysis which did not separate inflammatory bowel disease from functional 
gastrointestinal complaints.   
 
Cognitive Functioning.  Cognitive functioning and its relationship to psychological 
morbidity has been examined in two studies (59,60).  Castaneda et al. (59) investigated 
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a small sample of young people with inflammatory bowel disease and compared them 
to a control group with Juvenile Idiopathic Arthritis, and found no major cognitive 
deficits in either group.  Mild impairments in the verbal memory test were found in 
inflammatory bowel disease patients compared with controls, but depressive symptoms 
did not relate to the differences observed.  Jones and colleagues (60) examined 
cognitive and emotional processing by measuring pupillary responses which reflect 
cognitive and emotional processing, in a small cohort young people with inflammatory 
bowel disease, with and without depression and compared to healthy controls with and 
without depression  Exaggerated initial pupillary responses to negative emotional words 
in young people with inflammatory bowel disease with and without depression were 
observed, but not associated with disease severity or corticosteroid use.  These results 
suggest young people with inflammatory bowel disease experience more negative 
emotional stimuli compared to healthy controls.  
 
Family Functioning. Family functioning (defined as problem solving, communication, 
roles, affective responsiveness, affective involvement, and behavior control) has been 
examined in young people with inflammatory bowel disease with psychological 
morbidity (measured by parent-report).  Odell and colleagues (44) found that greater 
parent-reported externalizing behaviour in young people accounted for 26% of variance 
in family functioning, more than parental stress associated with caring for a child with a 
medical illness (measured by Pediatric Inventory for Parents) (44).  In contrast, 
internalising behaviours (depressive symptoms) in young people were not associated 
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with variance in family functioning.  These findings suggesting that parents/care-givers 
perception of young people with externalising behaviour (behavioural problems) result 
in an increased disruption to family functioning.  This may enable early identification of 
families in whom targeted psychological interventions may provide the greatest benefit.  
 
Spiritual Well-Being.  Spiritual well-being (existential and religious well-being 
measured by Spiritual Well-Being Scale (61)) and its relationship with psychological 
morbidity in young people with inflammatory bowel disease and healthy controls was 
investigated by Cotton et al. (42) with evidence of higher levels of existential well-being 
was associated with fewer depressive symptoms (r= -4.8, P<0.01).  In a multivariate 
model of analysis, lower existential well-being contributed 11% of variance of 
depressive symptoms (r2=0.18), but religious well-being not found to predict depressive 
symptoms.   
 
 
KE>h^/KE^ 
This review has demonstrated evidence that abdominal pain perception, sleep 
dysfunction, increased use of psychotropic drugs, non-adherence to medication, and 
negative illness perceptions are likely manifestations of psychological morbidity in 
young people with IBD.  Risk factors for psychological morbidity are likely to include 
increased disease severity, lower socioeconomic status, use of corticosteroids, 
family/parental factors and an older age at diagnosis of inflammatory bowel disease.  By 
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contrast, there is currently insufficient data regarding gender, ethnicity, inflammatory 
bowel disease type or duration and psychological morbidity.  
 
The evidence in this field is limited by key methodological and design inconsistencies.  
Nearly all studies thus far have examined only depression and anxiety, resulting in a 
significant gap in the literature with regards to other diagnosable psychological 
conditions.  There is wide variation in the assessment methods used to measure and 
define psychological morbidity and inflammatory bowel disease severity.  The studies 
included recruit predominantly paediatric populations, with none focusing specifically 
on young people aged between 16 and 24years which of importance due to the 
increasing prevalence of depression from pre-puberty to post puberty (62).  Future 
studies need a longitudinal design with prospective follow-up to determine causality, 
with increased representation of young people with severe inflammatory bowel disease 
requiring surgical interventions, those from ethnic minorities, and extending age of 
recruitment to 24 years.  To determine the full range of possible manifestations of 
psychological morbidity in young people with inflammatory bowel disease research is 
needed in health risk behaviours, educational/employment attainment and further work 
in the areas of illness perceptions, protective factors against psychological morbidity, 
cognitive functioning and health care utilisation.  Such data would directly inform cost-
benefit analysis to enable commissioning of psychological services with subsequent 
evidence with which to increasing the availability of commissioned psychological 
services for young people within paediatric and adult services. 
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The findings of this review suggest that psychological morbidity in young people with 
inflammatory bowel disease may have significant implications for disease management, 
such as medication adherence, self-report of symptoms of abdominal pain, and illness 
perceptions.  This may pose challenges for inflammatory bowel disease assessment and 
management in young people, for example with disease severity assessment tools, 
which assume a direct, causal link between disease activity and symptoms and which 
are used to guide clinical decisions regarding treatment escalation, continuation or the 
introduction of immunosuppressive medications.  Screening for psychological morbidity 
should be part of routine clinical practice for young people with inflammatory bowel 
disease. This is in line with EƵƌŽƉĞĂŶƌŽŚŶ ?ƐĂŶĚŽůŝƚŝƐKƌŐĂŶŝƐĂƚŝŽŶguidelines (11,12).  
Risk stratification in this vulnerable group might enable identification of subtypes of 
psychological morbidity and allow for development of individualised interventions.   
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